Or Yehuda, Israel, December 1, 2021: Restore Medical Ltd., a clinical-stage MedTech company developing cardiac implants for the treatment of congestive heart failure (CHF), today announced promising preliminary results of the First-in-Human clinical trial of ContraBand™, a breakthrough treatment for patients suffering from CHF. The minimally-invasive, catheter-delivered implants are used to treat patients with chronic left ventricular failure, where the heart is unable to pump sufficient oxygen-rich blood through the body.
Restore Medical has successfully implanted the ContraBand™ in its first patients at the ZNA medical center in Middelheim, Antwerp, Belgium, followed by Kaplan Medical Center in Israel.
“These first procedures are milestones in proving the ContraBand™ technology to be both safe and effective for heart failure patients,” said Gilad Marom, CEO of Restore Medical. “The positive impact this treatment can have on the millions of people suffering from CHF cannot be underestimated. Not only will it transform the quality of life of treated patients, but it will also reduce the enormous financial burden that comes as a result of patients being undertreated.”
The ContraBand™ is expected to relieve symptoms and improve patients’ quality of life by causing the healthy right ventricle to assist the failing left ventricle. The function of the implants is fully reversible even long after the procedure, which is unique in the field of cardiovascular implants.
CHF is a progressive, debilitating disease and is one of the leading causes of mortality, with less than half of patients surviving five years after diagnosis and only 30% surviving ten years. With 25% of patients returning to the hospital within a month of discharge, it is also the leading cause of repeat hospitalizations. CHF affects tens of millions of people worldwide, including 6.2 million in the United States alone, and is considered the largest unmet clinical and financial need facing global healthcare systems.